Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 19.5 mg intrauterine system for intrauterine use. It provides long‑acting reversible contraception and prevents pregnancy in women of reproductive age by locally releasing hormone over up to five years.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics for high‑volume medical product distribution and timely delivery to meet clinical demand.

Kyleena, a levonorgestrel-releasing intrauterine system, is used within the hormonal contraceptive pathway for birth control.

Contraception: Provides highly effective, long‑acting reversible birth control for women of reproductive age. Prevention of pregnancy: Reduces the risk of unintended pregnancy through continuous intrauterine hormone release. Family planning support: Enables women to plan and space pregnancies by offering reliable contraception for up to five years. Management of menstrual bleeding: May reduce menstrual blood loss and associated symptoms in some users.

Kyleena may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal pain - Headache

Serious or Rare Side Effects: - Uterine perforation - Device expulsion - Ectopic pregnancy - Pelvic inflammatory infection

Prior to Kyleena insertion and during use, several precautions should be observed to ensure patient safety.

Confirm non‑pregnancy: Verify the patient is not pregnant before device placement. Assess uterine anatomy: Contraindicated in significant uterine abnormalities such as bicornuate uterus. Screen for infection: Avoid insertion in the presence of active pelvic infection. Evaluate hormonal contraindications: Not recommended for women with active breast cancer or severe liver disease. Store at room temperature: Keep the device in its original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Kyleena can interact with other medicines that affect hormone levels or metabolic pathways.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): May markedly reduce contraceptive efficacy. - Rifampin and other strong enzyme inducers: Can lower levonorgestrel concentrations.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): May increase hormone exposure. - St. John’s wort: May modestly decrease effectiveness. - Combined hormonal therapies: May lead to additive hormonal effects.